Background and Objectives: Polydeoxyribonucleotides (PDRN), composed of DNA fragments derived from salmon DNA, is widely recognized for its regenerative properties. It has been extensively used in medical applications, such as dermatology and wound healing, due to its ability to enhance cellular metabolic activity, stimulate angiogenesis, and promote tissue regeneration. In the field of dentistry, PDRN has shown potential in promoting periodontal healing and bone regeneration. This study aims to investigate the effects of PDRN on the morphology, survival, and osteogenic differentiation of gingiva-derived stem cell spheroids, with a focus on its potential applications in tissue engineering and regenerative dentistry. Materials and Methods: Gingiva-derived mesenchymal stem cells were cultured and formed into spheroids using microwells. The cells were treated with varying concentrations of PDRN (0, 25, 50, 75, and 100 μg/mL) and cultivated in osteogenic media. Cell morphology was observed over seven days using an inverted microscope, and viability was assessed with Live/Dead Kit assays and Cell Counting Kit-8. Osteogenic differentiation was evaluated by measuring alkaline phosphatase activity and calcium deposition. The expression levels of osteogenic markers RUNX2 and COL1A1 were quantified using real-time polymerase chain reaction. RNA sequencing was performed to assess the gene expression profiles related to osteogenesis. Results: The results demonstrated that PDRN treatment had no significant effect on spheroid diameter or cellular viability during the observation period. However, a PDRN concentration of 75 μg/mL significantly enhanced calcium deposition by Day 14, suggesting increased mineralization. RUNX2 and COL1A1 mRNA expression levels varied with PDRN concentration, with the highest RUNX2 expression observed at 25 μg/mL and the highest COL1A1 expression at 75 μg/mL. RNA sequencing further confirmed the upregulation of genes involved in osteogenic differentiation, with enhanced expression of RUNX2 and COL1A1 in PDRN-treated gingiva-derived stem cell spheroids. Conclusions: In summary, PDRN did not significantly affect the viability or morphology of gingiva-derived stem cell spheroids but influenced their osteogenic differentiation and mineralization in a concentration-dependent manner. These findings suggest that PDRN may play a role in promoting osteogenic processes in tissue engineering and regenerative dentistry applications, with specific effects observed at different concentrations.

In cases where the bone presence is <4 mm, the lateral approach is typically the first approach considered. Nevertheless, for patients who prefer minimally invasive procedures or wish to reduce postoperative discomfort, the crestal approach is a viable option. The objective of this study was to investigate the potential of crestal sinus augmentation for achieving adequate bone in individuals with residual bone measuring <3 mm. The study comprised 11 participants (63.6 ± 10.9 years of age) who were treated at Seoul St. Mary’s Hospital between 2021 and 2023 and received crestal approach sinus augmentation due to insufficient bone density of <3 mm using the crestal approach kit. Pre-augmentation and post-augmentation cone-beam computed tomographic images were analyzed using the imaging software to measure vertical bone height, bucco–palatal width, and mesio–distal width. Before the intervention, the height of the vertical bone was 2.1 ± 0.5 mm, while the width from buccal to palatal was 10.6 ± 2.9 mm, and the width from mesial to distal was 9.9 ± 1.2 mm. Following the intervention, these measurements increased to 8.8 ± 0.9 mm, 12.2 ± 2.2 mm, and 10.2 ± 1.2 mm, respectively. The change in height of the vertical bone was 6.7 ± 1.0 mm, in bucco–palatal width was 1.6 ± 1.4 mm, and in mesio–distal width was 0.3 ± 0.4 mm. The results revealed a significant rise in the height of the vertical bone and bucco–palatal width. Crestal sinus augmentation has been demonstrated to be a highly effective approach for achieving an adequate quantity of bone in patients with residual bone <3 mm. Nonetheless, further observation is required to evaluate the long-term prognosis of the procedures.

Background and Objectives: Vascular endothelial growth factor (VEGF) is a protein which stimulates the formation of new blood vessels, playing a crucial role in processes such as wound healing and tumor growth. Methods: This study investigated the effects of VEGF on cell viability and osteogenic differentiation in mesenchymal stem cell (MSC) spheroids. Stem cell spheroids were fabricated using concave microwells and cultured with VEGF at concentrations of 0, 0.01, 0.1, 1, and 10 ng/mL. Morphological assessments were conducted on days 1, 3, 5, and 7, while cell viability was evaluated using the LIVE/DEAD assay and Cell Counting Kit-8. Alkaline phosphatase activity (ALP) and calcium deposition were measured to assess osteogenic differentiation, and qPCR was used to analyze osteogenic marker expression. Results: The spheroids maintained their shape across all VEGF concentrations, with the largest diameter being at 0.01 ng/mL on day 1, which decreased over time. Cell viability was highest at 0.01 ng/mL VEGF, while calcium deposition peaked at 0.1 ng/mL. Osteogenic markers, including RUNX2, osteocalcin, and COL1A1, showed significant upregulation at 1 ng/mL VEGF. Conclusions: These results suggest that VEGF enhances early osteogenic differentiation in MSC spheroids, indicating its potential for bone repair and tissue regeneration. VEGF could be applied in clinical settings for bone healing, fracture repair, and regenerative dentistry treatments.

Background and Objectives: Dexamethasone has been widely researched for its ability to promote osteogenic differentiation in mesenchymal stem cells in basic research. This study focused on examining the effects of dexamethasone on both cell viability and osteogenic differentiation in three-dimensional stem cell spheroids. Materials and Methods: These spheroids were created using concave microwells and exposed to dexamethasone at concentrations ranging from 0 μM to 100 μM, including intermediate levels of 0.1 μM, 1 μM, and 10 μM. Microscopic analysis was used to qualitatively assess cellular viability, while a water-soluble tetrazolium salt-based assay provided quantitative viability data. Osteogenic differentiation was evaluated by measuring alkaline phosphatase activity and calcium deposition using Alizarin Red staining. Additionally, the expression levels of genes associated with osteogenesis were measured through quantitative polymerase chain reaction. Results: The spheroids successfully self-assembled within the first 24 h and maintained their structural integrity over a seven-day period. Analysis of cell viability showed no statistically significant differences across the various dexamethasone concentrations tested. Although there was an observed increase in alkaline phosphatase activity and calcium deposition following dexamethasone treatment, these differences were not statistically significant. RUNX2 gene expression was upregulated in the 1 μM, 10 μM, and 100 μM groups, while COL1A1 expression significantly increased at 0.1 μM and 1 μM. Conclusions: These results indicate that dexamethasone supports cell viability and enhances RUNX2 and COL1A1 expression in stem cell spheroids.

Evaluating the implant site immediately after implant removal is crucial for assessing its condition and ensuring morphological stability. Immediate reconstruction at the time of implant removal has been proposed as a strategy to preserve alveolar ridge width. This study aims to evaluate whether immediate alveolar bone reconstruction at the time of implant removal provides comparable or superior dimensional stability of the alveolar ridge compared to staged reconstruction approaches. The null hypothesis of this study is that there is no significant difference in alveolar bone dimensions between immediate and staged reconstructions following implant removal. This retrospective study included seven participants, consisting of six males and one female. The participants were categorized into three groups based on the treatment approach following implant removal. In Group 1, no bone grafting was performed after implant removal. In Group 2, bone grafting was conducted following implant removal, with an adequate healing period before implant placement. In Group 3, bone grafting was performed simultaneously with implant removal. Cone-beam computed tomography (CBCT) imaging was conducted before implant removal (T0), after implant removal or bone grafting (T1), and after implant placement (T2). All removed implants were successfully replaced with new ones, regardless of bone grafting. In terms of alveolar ridge width at 1 mm below the crest, Group 1 exhibited the greatest reduction (ΔT1 − T0 = −5.1 ± 3.7 mm), while Group 2 showed a mild increase (+1.1 ± 2.6 mm), and Group 3 had a moderate decrease (−1.3 ± 1.0 mm). This suggests that delayed bone grafting can better preserve or enhance bone volume during healing. A reduction in buccal ridge height between T1 and T0 (ΔT1 − T0) was observed, particularly in Group 1. In contrast, an increase in buccal ridge height was most pronounced in Group 2. Although immediate reconstruction (Group 3) did not result in statistically significant gains, it achieved successful implant placement without complications and reduced the total treatment duration, which might be beneficial from a clinical efficiency and patient satisfaction standpoint. Therefore, staged bone grafting (Group 2) appears to offer greater dimensional stability, particularly in maintaining ridge height, whereas immediate reconstruction (Group 3) remains a clinically viable alternative for stable healing in select cases, especially when shorter treatment timelines are prioritized.

Background and Objectives: Evidence directly comparing crestal and lateral approaches for maxillary sinus floor augmentation remains uncertain. We compared their outcomes and assessed certainty of evidence. Materials and Methods: Randomized trials directly comparing both approaches were included. MEDLINE/PubMed, Embase, and the Cochrane Library were searched from inception to 30 July 2026, supplemented by non-systematic Google Scholar searches. Risk of bias and evidence certainty were assessed using RoB 2 and GRADE. Outcomes were pooled as risk ratios (RRs), mean differences (MDs), or standardized mean differences (SMDs), with 95% confidence intervals (CIs). The protocol was registered in PROSPERO (CRD420261447905). Results: Thirteen randomized trials (17 reports) were included. No statistically significant differences were found for implant failure (RR 0.50, 95% CI 0.10–2.61), membrane perforation (RR 0.63, 95% CI 0.29–1.38), marginal bone loss at 12 months (MD −0.08 mm, 95% CI −0.31–0.15), vertical bone gain at 12 months (MD −0.81 mm, 95% CI −1.94–0.33) or 6 months (MD −1.07 mm, 95% CI −2.50–0.36), or postoperative pain (SMD −1.56, 95% CI −3.31–0.20). Certainty was low to very low. Conclusions: Current evidence does not establish superiority of either approach. Selection should reflect residual bone height, sinus anatomy, treatment objectives, and operator experience.